Meeting Proceedings & Findings

AMCP's Meeting Reports

AMCP will occasionally publish highlights from AMCP and other conferences designed for those in managed care pharmacy. Highlights include summaries of select featured sessions and posters. Meetings published currently include the AMCP Annual 2023, Psych Congress 2023, and the American Psychiatric Association 2023 Annual Meeting.

AMCP Market Insights Roundtable on Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive, and fatal neurodegenerative disease characterized by loss of motor neurons in the brain and spinal cord. On April 27, AMCP convened an expert panel of clinical and managed care stakeholders to increase understanding on how payers can inform strategies to improve the care and treatment of those impacted by ALS.
Managed Care Practice Issues

Roundtable on Optimizing the Management of Inherited Blood Disorders

Hemophilia, sickle cell disease (SCD), and beta-thalassemia (β thal) are inherited blood disorders likely to see multiple significant novel therapies approved in the near future, including the possibility for partial or complete cures with gene therapies. To understand the appropriate and cost-effective use of treatments for inherited blood disorders, AMCP convened an expert panel of managed care stakeholders in October 2022.

Roundtable on BKTis in Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is characterized by a progressive accumulation of leukemia cells in the peripheral blood, bone marrow, and lymphoid tissues. Bruton tyrosine kinase inhibitors (BTKis) are a preferred treatment of patients with CLL. In September 2022, AMCP convened an expert panel of managed care stakeholders to better understand the clinical dynamics of treatment choice in patients with CLL and the key management considerations in CLL with a focus on BTKis.

AMCP Biosimilars Operational Readiness Initiative

The Biosimilars Operational Readiness group is an initiative focused on developing resources to aid in the assessment and implementation of biosimilars when formulary coverage is approved. This group launched in Q4 2022.
Biosimilars

AMCP Digital Therapeutics Advisory Group

The Digital Therapeutics Advisory Group is focused on developing resources for payers on when they should evaluate products, what manufacturers should communicate, and understanding how Digital Therapeutics are included in drug compendia. This advisory group is active from March 2022-February 2023.
Digital Therapeutics